Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems
Pemetrexed (PMX) is an antifolate drug utilized in the treatment of non-small cell lung cancer. For studies of potential macromolecular carriers for PMX, fast and precise methods were developed to determine the bound and free drug contained in investigated conjugate preparations. The analysis of the...
Saved in:
Main Authors: | Ciekot Jarosław, Goszczyński Tomasz Marek, Boratyński Janusz |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2016-03-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.1515/acph-2016-0001 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Status of macromolecular crystallography beamlines at SSRF
by: Huating Kong, et al.
Published: (2025-01-01) -
CD146 promotes resistance of NSCLC brain metastases to pemetrexed via the NF-κB signaling pathway
by: Hao Qu, et al.
Published: (2025-01-01) -
N-Oxalylglycine-Conjugated Hyaluronic Acid as a Macromolecular Prodrug for Therapeutic Angiogenesis
by: Andrew H. DeMaria, et al.
Published: (2025-01-01) -
Long-term survival with pemetrexed-based chemotherapy in a patient with metastatic lung adenocarcinoma of unclear primary origin harboring MTHFR C677T(T/T) mutation: a case report
by: Yuan Yu, et al.
Published: (2025-01-01) -
Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA
by: Tobias Solli Iveland, et al.
Published: (2025-01-01)